Q2 2026 Corcept Therapeutics Inc Earnings Call Transcript
Key Points
- Record new prescriptions and first-time prescribers in Cushing's syndrome business, driving strong demand.
- Lifyorli launch in platinum-resistant ovarian cancer generated $47.6 million in first-quarter revenue with over 1,300 patients started.
- Positive CATALYST and MOMENTUM trial results are increasing physician awareness and screening for hypercortisolism.
- Relacorilant NDA resubmission accepted with PDUFA date of December 17, 2026, offering potential for accelerated growth.
- Promising Phase II DAZALS trial results for dazucorilant in ALS showed 84% reduction in risk of death at one year.
- Relacorilant's approval delayed due to a complete response letter from FDA, with resubmission only accepted in June 2026.
- Dazucorilant's gastrointestinal tolerability issues caused most discontinuations in the DAZALS trial.
- Lifyorli's duration of therapy is still early to assess, with limited long-term patient follow-up data.
- Potential competition from other therapies in Cushing's syndrome and oncology markets could impact growth.
- Dependence on successful Phase IIb MONARCH trial results for miricorilant in MASH, with data expected later this year.
Thank you for standing by, and welcome to the Corcept Therapeutics second quarter 2026 earnings conference call. (Operator Instructions) As a reminder, today's program is being recorded.
And now I'd like to introduce your host for today's program, Atabak Mokari, CFO. Please go ahead, sir.
Hello, everyone. Good afternoon, and thank you for joining us. Today, we issued a press release announcing our financial results for the second quarter and providing a corporate update. A copy is available at corcept.com. Our complete financial results will be available when we file our Form 10-Q with the SEC.
Today's call is being recorded. A replay will be available at the Investors, Past Events tab of our website. Statements during this call, other than statements of historical fact, are forward-looking statements based on our plans and expectations that are subject to risks and uncertainties, which might cause actual results to be materially different from those such statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
